首页|Identification of Expression Pattern and Clinical Significance of the Small Cajal Body-specific RNA SCARNA16 in Hepatocellular Carcinoma
Identification of Expression Pattern and Clinical Significance of the Small Cajal Body-specific RNA SCARNA16 in Hepatocellular Carcinoma
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
维普
万方数据
Background and Aims: For high morbidity and mortality, hepatocellular carcinoma (HCC) becomes a major health issue worldwide. Nowadays, numerous non-coding RNAs (ncRNAs) are known to regulate the occurrence and patho-genesis of tumors. Some ncRNAs have also been developed as tumor biomarkers and therapeutic targets. However, the potential function of the small Cajal body-specific RNA (scaRNA) SCARNA16, a newly identified ncRNA, remains to be explored in HCC. Methods: In both HCC cell lines and specimens from 120 enrolled patients, the expression val-ues of SCARNA16 were detected. We divided patients into SCARNA16 high and low expression subgroups, and then analyzed the difference of various clinical characteristics and prognosis data between subgroups. Results: Compared to paired controls, SCARNA16 was significantly down-regulated in HCC cell lines and clinical specimens (p<0.01). Besides, HCC patients with lower SCARNA16 expression commonly presented with larger and more tumor lesions, more ves-sel carcinoma emboli, more capsular invasion and higher TNM stages (p<0.05). Moreover, SCARNA16 expression was negatively correlated with postoperative prognosis of HCC patients in 5-year follow-up, including tumor-free survival (TFS) (median time of low vs. high subgroups: 14 vs. 48 months, p=0.006) and overall survival (OS) (median time of low vs. high subgroups: 39 vs. 52 months, p=0.001). Besides, SCARNA16 acted as an independent prognostic bio-marker in TFS (hazard ratio [HR]: 0.578, 95％ CI: 0.345–0.969, p=0.038) and OS (HR: 0.366, 95％ CI: 0.178–0.752, p=0.006). Conclusions: Low expression patterns of SCAR-NA16 remarkably associated with severe clinical status and poor survival of patients, suggesting that SCARNA16 pos-sesses potency as a novel biomarker for HCC.
Department of Hepatobiliary and Pancreatic Surgery,The Second Affiliated Hospital,Zhejiang University School of Medi-cine,Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province,Re-search Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province,Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University,Clinical Research Center of Hepatobi
Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province,Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province,Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University,Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province,Zhejiang University Cancer Center,Hangzhou,Zhejiang,China
国家自然科学基金国家自然科学基金Key Research and Development Program of Zhejiang Prov-inceKey Research and Development Program of Zhejiang Prov-ince
NETL
NSTL
维普
万方数据
